Holliston, Mass.-based CRO Veristat said Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms serving developing pharmaceutical and medical device companies, has made a growth equity investment in the company.

Veristat has 20 years of expertise supporting clinical trials for pharmaceutical, biotechnology, and medical device companies. Its services include trial design, biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings.

“Many developing CROs are filled with scientific talent which routinely gets distracted from maximizing their client impact by the need to manage their business. Our partnership will allow Veristat to focus its scientific expertise,” said Patrick Flanagan, managing partner with Variance.

Comprised of executives from the pharmaceutical and financial industries, Variance invests in promising companies in the life sciences marketplace to help fuel growth strategies.